United States Cell Therapy Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Cell Therapy Market reached US$ 6.52 Billion in 2024 and is expected to reach US$ 48.98 Billion by 2033, growing at a CAGR of 21.4% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cell-therapy-market?sb

Key Development:

United States: Recent Industry Developments

✅ In December 2025, Kite (a Gilead Sciences company) presented Phase‐1 data for its next‐generation bicistronic CAR‐T therapies (KITE‐753 and KITE‐363) showing encouraging complete response rates and a favorable safety profile in relapsed/refractory B‐cell lymphoma.

✅ In November 2025, the global cell and gene therapy sector saw a surge in financing, partnerships and clinical‐trial activity underlining renewed momentum as the field transitions from early promise to broader scale development and commercialization.

✅ In November 2025, A‐SEEDS Co., Ltd. (Japan‐based) partnered with Cell Therapies Pty Ltd. (Australia) for GMP manufacturing of A‐SEEDS' lead non‐viral CAR‐T cell candidate enabling global clinical‐trial supply and reinforcing cross‐border manufacturing collaboration.

✅ In October 2025, In‐vivo cell therapies and non‐viral / off‐the-shelf approaches are becoming bright spots in the CGT (cell & gene therapy) landscape pointing to a shift in focus toward scalable, next‐gen cell therapy platforms.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cell-therapy-market

Japan: Recent Industry Developments

✅ In November 2025, Teijin Limited formed a strategic alliance with BioVaram to explore expansion of regenerative medicine products and medical‐device usage in India and Japan signalling a push for broader adoption of cell therapy and regenerative products beyond Japan.

✅ In November 2025, Teijin (via its CDMO arm) and Cell Therapies Pty Ltd signed a Memorandum of Understanding to strengthen regional manufacturing infrastructure for cell and gene therapies aimed at improving access and streamlining cross-border regulatory and supply‐chain operations.

✅ In November 2025, A-SEEDS and Cell Therapies announced a manufacturing partnership for A-SEEDS' novel CAR‐T cell therapy candidate, paving way for GMP production and planned clinical trials a concrete step toward bringing Japanese‐developed cell therapies into global trials.

✅ In October 2025, it was reported that cell and gene therapy manufacturing and regulatory‐infrastructure development in Japan are gaining strategic attention, reflecting a broader shift toward making Japan a vital hub in CGT scale‐up and commercialization.

Key Players:

=> Gilead Sciences, Inc., Novartis AG, Vericel Corporation, CO.DON GmbH, Bristol Myers Squibb company., IOVANCE Biotherapeutics, Inc., Dendreon Pharmaceuticals LLC., Enzyvant Therapeutics GmbH., CellTrans., and Gamida Cell Inc., among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cell-therapy-market?sb

Key Segments:

By Source

Autologous cell therapies lead with 55% share, driven by reduced risk of immune rejection, personalized treatment approaches, and widespread adoption in oncology and musculoskeletal therapies. Allogenic sources account for 45%, supported by off-the-shelf availability, scalable production, and increasing research in immunodeficiency and Graft-versus-Host Disease (GVHD) management.

By Cell Type

Stem cells dominate with 65% share, fueled by applications in regenerative medicine, oncology, and musculoskeletal repair, supported by clinical trials and increasing approvals for stem cell therapies. Non-stem cells hold 35%, reflecting niche applications in immunotherapy, blood-based treatments, and targeted cellular interventions.

By Application

Oncology leads with 30% share, driven by cell-based immunotherapies, personalized cancer treatments, and ongoing clinical development pipelines. Musculoskeletal conditions account for 20%, supported by regenerative therapy adoption for cartilage, bone, and joint repair. Gastrointestinal (GIT) conditions represent 15%, fueled by emerging research in inflammatory bowel diseases and gut regeneration. Immunodeficiency disorders hold 10%, reflecting therapeutic applications for rare and chronic conditions. Graft-versus-host disease (GVHD) accounts for 10%, driven by allogenic cell therapy innovations. Other applications make up 15%, including autoimmune diseases, cardiovascular, and dermatological indications.

By Region

North America - 40% Share
North America leads with 40%, driven by advanced research infrastructure, high adoption of autologous stem cell therapies, strong regulatory support, and robust clinical trial activities in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by healthcare infrastructure, increasing investments in regenerative medicine, and adoption across Germany, U.K., France, Italy, and other key markets.

Asia Pacific - 20% Share
Asia Pacific accounts for 20%, fueled by growing healthcare access, increasing R&D investments, and adoption of cell therapies in China, Japan, India, and Southeast Asia.

South America - 7% Share
South America holds 7%, driven by rising awareness, healthcare modernization, and emerging clinical applications in Brazil, Argentina, and neighboring countries.

Middle East & Africa - 8% Share
The Middle East & Africa represent 8%, supported by increasing medical infrastructure, government initiatives for advanced therapies, and adoption of stem cell treatments in GCC countries, South Africa, and other regional hubs.

FAQ

What is the current size of the Cell Therapy Market?

A: In 2024, the Cell Therapy Market was valued at US$ 6.52 Billion, reflecting its strong industry presence.

Q2: How large is the Cell Therapy Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Cell Therapy Market will grow to around US$ 48.98 Billion , demonstrating significant expansion.

Q3: What is the growth rate of the Cell Therapy Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 21.4% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.